BlackRock
LTRN icon

BlackRock’s Lantern Pharma LTRN Stock Holding History

BlackRock’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$62K Buy
45,267
+1,014
+2% +$2.83K ﹤0.01% 5074
2025
Q4 		$134K Buy
44,253
+1,163
+3% +$4.33K ﹤0.01% 4825
2025
Q3 		$187K Buy
43,090
+815
+2% +$3.4K ﹤0.01% 4687
2025
Q2 		$134K Buy
42,275
+2,027
+5% +$6.84K ﹤0.01% 4771
2025
Q1 		$142K Sell
40,248
-348
-0.9% -$1.44K ﹤0.01% 4675
2024
Q4 		$130K Buy
40,596
+116
+0.3% +$397 ﹤0.01% 4725
2024
Q3 		$149K Buy
40,480
+639
+2% +$2.63K ﹤0.01% 4594
2024
Q2 		$186K Buy
39,841
+20,182
+103% +$121K ﹤0.01% 4564
2024
Q1 		$173K Sell
19,659
-303
-2% -$1.62K ﹤0.01% 4624
2023
Q4 		$85.4K Sell
19,962
-186
-0.9% -$656 ﹤0.01% 4847
2023
Q3 		$68.7K Sell
20,148
-651
-3% -$2.96K ﹤0.01% 4941
2023
Q2 		$117K Sell
20,799
-651
-3% -$3.36K ﹤0.01% 4866
2023
Q1 		$104K Buy
21,450
+558
+3% +$2.93K ﹤0.01% 4945
2022
Q4 		$126K Buy
20,892
+372
+2% +$1.86K ﹤0.01% 4970
2022
Q3 		$98K Sell
20,520
-2,242
-10% -$12.1K ﹤0.01% 5180
2022
Q2 		$129K Sell
22,762
-312
-1% -$1.86K ﹤0.01% 5162
2022
Q1 		$164K Sell
23,074
-936
-4% -$6.25K ﹤0.01% 5159
2021
Q4 		$190K Buy
24,010
+936
+4% +$8.55K ﹤0.01% 5116
2021
Q3 		$258K Sell
23,074
-2,043
-8% -$26.4K ﹤0.01% 4927
2021
Q2 		$366K Buy
25,117
+1,467
+6% +$22.7K ﹤0.01% 4768
2021
Q1 		$429K Buy
23,650
+18,409
+351% +$323K ﹤0.01% 4629
2020
Q4 		$101K Buy
5,241
+232
+5% +$4.01K ﹤0.01% 4583
2020
Q3 		$94K Buy
+5,009
New +$72.5K ﹤0.01% 4525

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

BlackRock's LTRN Position: Q1 2026 in Review

BlackRock increased its Lantern Pharma (LTRN) stake by 2.3% in Q1 2026, buying an estimated $2.83K and bringing the position to 45,267 shares worth $62K. The position accounts for ﹤0.01% of the portfolio, ranked #5074.

BlackRock first reported a position in LTRN in Q3 2020 and has held it in 23 quarters since. The position peaked at $429K in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • BlackRock held 45,267 shares of Lantern Pharma worth $62K as of Q1 2026.
  • BlackRock bought 1,014 Lantern Pharma shares in Q1 2026, an estimated $2.83K.
  • Lantern Pharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5074 holding.
  • BlackRock first reported a position in Lantern Pharma in Q3 2020 and has held it in 23 quarters since.
  • BlackRock's Lantern Pharma position peaked at $429K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.